Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Free Cash Flow (2016 - 2025)

Altimmune (ALT) has disclosed Free Cash Flow for 16 consecutive years, with -$19.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 6.48% to -$19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$67.5 million through Dec 2025, up 15.42% year-over-year, with the annual reading at -$67.5 million for FY2025, 15.41% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$19.4 million at Altimmune, down from -$11.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$11.9 million in Q3 2025, with the low at -$27.1 million in Q3 2024.
  • Average Free Cash Flow over 5 years is -$18.8 million, with a median of -$18.2 million recorded in 2024.
  • The sharpest move saw Free Cash Flow tumbled 444.68% in 2021, then skyrocketed 56.13% in 2025.
  • Over 5 years, Free Cash Flow stood at -$22.1 million in 2021, then rose by 21.57% to -$17.3 million in 2022, then grew by 4.68% to -$16.5 million in 2023, then fell by 10.48% to -$18.3 million in 2024, then fell by 6.48% to -$19.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$19.4 million, -$11.9 million, and -$19.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.